Sonoma Pharmaceuticals (SNOA) Operating Margin (2010 - 2025)

Sonoma Pharmaceuticals' Operating Margin history runs 16 years deep, the most recent figure standing at 15.59% for Q4 2025.

• In Q4 2025, Operating Margin rose 1334.0% year-over-year to 15.59%; the TTM figure through Dec 2025 stood at 15.61% (up 1633.0% YoY), while the FY2025 annual figure was 25.97%, up 1095.0% from the prior year.
• Operating Margin was 15.59% for Q4 2025 at Sonoma Pharmaceuticals, down from 6.01% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 6.01% in Q3 2025 to a low of 133.16% in Q1 2022.
• Historically, Operating Margin has averaged 39.63% across 5 years, with a median of 28.1% in 2024.
• The sharpest annual moves came in 2021 and 2023: Operating Margin slumped 5569 bps in 2021, then jumped 9510 bps in 2023.
• A 5-year view of Operating Margin shows it stood at 33.01% in 2021, then plunged by 89 bps to 62.3% in 2022, then jumped by 57 bps to 26.9% in 2023, then fell by 8 bps to 28.93% in 2024, then jumped by 46 bps to 15.59% in 2025.
• The last three Operating Margin figures came in at 15.59% (Q4 2025), 6.01% (Q3 2025), and 27.27% (Q2 2025), per Business Quant data.